ProBio

ProBio is an outcome-adaptive, multi-arm, open-label, multiple assignment randomized biomarker driven trial in patients with metastatic prostate cancer

[ProBio @ProBioTrial]

📣 Pleased to share the publication of the ProBio-mHSPC trial protocol in @EUplatinum Focus: a ctDNA-driven platform trial designed to personalize treatment intensity for patients with metastatic hormone-sensitive prostate cancer.

[ProBio @ProBioTrial]

#ProstateCancer #mCRPC #UroOncology #MedicalOncology #PrecisionOncology #ClinicalTrials #ctDNA #Urology #Oncology #EvidenceBasedMedicine #EAU #PrecisionMedicine

[ProBio @ProBioTrial]

📣 Published in @EUplatinum : our Letter to the Editor on the @myESMO Clinical Practice Guideline for advanced and metastatic prostate cancer.

⚕️The guideline notes the lack of mCRPC trials comparing ARPI with docetaxel-based chemotherapy

🌐https://t.co/LJvC2xvIMm

[ProBio @ProBioTrial]

💡However, comparative randomised evidence is available from the ProBio trial (NCT03903835) in men with ARPI-naïve mCRPC and detectable ctDNA. Compared to taxanes, ARPIs were associated with:
✅ Longer time of clinical benefit (PCWG3)
✅ Longer overall survival
✅ Fewer (S)AE

[ProBio @ProBioTrial]

🙏 A sincere thank you to all participating patients, sites, investigators, clinical teams, collaborators, companies and funders supporting this effort.

#ProstateCancer #ClinicalTrials #PrecisionOncology #LiquidBiopsy #ctDNA #mHSPC #Oncology #Urology #PersonalizedMedicine

[ProBio @ProBioTrial]

📣 Pleased to share the publication of the ProBio-mHSPC trial protocol in @EUplatinum Focus: a ctDNA-driven platform trial designed to personalize treatment intensity for patients with metastatic hormone-sensitive prostate cancer.

[ProBio @ProBioTrial]

🎯By integrating liquid biopsy profiling, multi-arm platform methodology, patient-reported outcomes, and international collaboration, ProBio-mHSPC seeks to move from “one-size-fits-all” towards more precise, evidence-based care.

[ProBio @ProBioTrial]

This research was made possible by the support of:
@ALFmedicin , @Cancerfonden , Radiumhemmet Research Funds, @Prostatacancerforbundet, @Vetenskapsradet , Krebsliga beider Basel, & @KomOpTegenKanker

THANK YOU! 🙏

[8/8]

#CancerResearchMatters

[ProBio @ProBioTrial]

🚨 New Study Alert! 🚨

What if a blood test 🩸 could infer prognosis in advanced prostate cancer? Our latest #ProBio trial study reveals the prognostic power of circulating tumor DNA (ctDNA) 🧬 in #mCRPC

A thread 🧵👇 #CancerResearch #ProstateCancer

[1/8]

[ProBio @ProBioTrial]

What’s next?

🏥 @ProBioTrial will explore treatment de-escalation for low-ctDNA patients

🔬 Future trials should integrate ctDNA fraction 🩸🧬 as a stratification tool

👨‍⚕️ ctDNA may guide guide #PrecisionMedicine in all #ProstateCancer patients?

[7/8]

[UroToday.com @urotoday]

AR pathway inhibitors vs taxanes in #mCRPC #ProBio trial. @BramDL @ugent joins @zklaassen_md @GACancerCenter to discuss the #ProBio trial, a groundbreaking platform study in metastatic prostate cancer. Findings show that AR pathway inhibitors often outperform taxane-based chemo in mCRPC, with outcomes influenced by specific genomic markers. #WatchNow > https://t.co/RGUgW5KhdI @ProBioTrial

[UroToday.com @urotoday]

AR pathway inhibitors vs taxanes in #mCRPC #ProBio trial. @BramDL @ugent joins @zklaassen_md @GACancerCenter to discuss the #ProBio trial, a groundbreaking platform study in metastatic prostate cancer. Findings show that AR pathway inhibitors often outperform taxane-based chemo in mCRPC, with outcomes influenced by specific genomic markers. #WatchNow > https://t.co/RGUgW5KhdI @ProBioTrial

[UroToday.com @urotoday]

AR pathway inhibitors vs taxanes in #mCRPC #ProBio trial. @BramDL @ugent joins @zklaassen_md @GACancerCenter to discuss the ProBio trial, a groundbreaking platform study in metastatic prostate cancer. Findings show that AR pathway inhibitors often outperform taxane-based chemo in mCRPC, with outcomes influenced by specific genomic markers. #WatchNow > https://t.co/RGUgW5KhdI

[Piet Ost @piet_ost]

Don’t forget the @ProBioTrial is an investigator-initiated trial! Crazy level of commitment of everyone involved.